Tejara Capital LTD Cardiol Therapeutics Inc. Transaction History

Tejara Capital LTD

$192 Billion
Q3 2025

A detailed history of Tejara Capital LTD transactions in Cardiol Therapeutics Inc. stock. As of the latest transaction made, Tejara Capital LTD holds 2,630,122 shares of CRDL stock, worth $2.68 Million. This represents 1.47% of its overall portfolio holdings.

Number of Shares

2,630,122

Previous 3,265,819 19.47%

Holding current value

$2.68 Million

Previous $4.44 Billion 36.64%

% of portfolio

1.47%

Previous 2.06%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 04, 2025	SELL	$0.99 - $1.54 $629,340 - $978,973	-635,697 Reduced 19.47%	2,630,122 $2.81 Billion
Q2 2025 Aug 13, 2025	BUY	$0.81 - $1.47 $57,371 - $104,118	70,829 Added 2.22%	3,265,819 $4.44 Billion
Q1 2025 May 13, 2025	BUY	$0.96 - $1.46 $76,370 - $116,147	79,553 Added 2.55%	3,194,990 $3.1 Billion
Q4 2024 Feb 10, 2025	BUY	$1.25 - $2.07 $1.68 Million - $2.78 Million	1,344,167 Added 75.89%	3,115,437 $3.99 Billion
Q3 2024 Nov 13, 2024	BUY	$1.83 - $2.48 $89,719 - $121,586	49,027 Added 2.85%	1,771,270 $3.51 Billion

Q2 2024 Aug 13, 2024	BUY	$1.67 - $2.97 $129,981 - $231,164	77,833 Added 4.73%	1,722,243 $3.48 Billion
Q1 2024 May 14, 2024	BUY	$0.88 - $2.06 $464,405 - $1.09 Million	527,734 Added 47.26%	1,644,410 $2.98 Billion
Q4 2023 Feb 12, 2024	BUY	$0.67 - $1.0 $315,716 - $471,219	471,219 Added 73.01%	1,116,676 $942 Million
Q3 2023 Nov 13, 2023	BUY	$0.76 - $1.19 $112,780 - $176,591	148,396 Added 29.85%	645,457 $578 Million
Q2 2023 Aug 11, 2023	BUY	$0.45 - $0.97 $25,395 - $54,741	56,435 Added 12.81%	497,061 $442 Million
Q4 2022 Feb 13, 2023	BUY	$0.48 - $1.0 $211,500 - $440,626	440,626 New	440,626 $225 Million

Others Institutions Holding CRDL

# of Institutions

Shares Held

7.53M

Call Options Held

25K

Put Options Held

View Full List

About Cardiol Therapeutics Inc.

Ticker CRDL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 61,942,500
Market Cap $63.2M
Description
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product is CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate t...

More about CRDL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Tejara Capital LTD, based on Form 13F filings with the SEC.

News

Stay updated on Tejara Capital LTD with notifications on news.

Account

Tejara Capital LTD Cardiol Therapeutics Inc. Transaction History